

J Diabetes Metab. Author manuscript; available in PMC 2015 September 23.

Published in final edited form as:

J Diabetes Metab. 2015 June 01; 6(6): 1–7. doi:10.4172/2155-6156.1000556.

# Effects of Alpha-Lipoic Acid on Oxidative Stress and Kinin Receptor Expression in Obese Zucker Diabetic Fatty Rats

Adil El Midaoui<sup>1,#</sup>, Sébastien Talbot<sup>1,#</sup>, Karim Lahjouji<sup>1</sup>, Jenny Pena Dias<sup>1</sup>, I. George Fantus<sup>2</sup>, and Réjean Couture<sup>1,\*</sup>

<sup>1</sup>Department of Molecular and Integrative Physiology, Faculty of Medicine, Université de Montréal, PO Box 6128, Station City-Center, Montréal, Qc, H3C 3J7 Canada

<sup>2</sup>Department of Medicine, Mount Sinai Hospital and University Health Network, Banting and Best Diabetes Center, University of Toronto, Toronto, On, M5G 2C4 Canada

# Abstract

**Objective**—To investigate the impact of alpha-lipoic acid on superoxide anion production and NADPH oxidase activity as well as on the expression of kinin B1 and B2 receptors in key organs of obese Zucker Diabetic Fatty rats.

**Methods**—Superoxide anion production was measured by lucigenin chemiluminescence. Kinin B1 and B2 receptors expression was measured at protein and mRNA levels by western blot and qRT-PCR in key organs of Zucker Diabetic Fatty and Zucker lean control rats treated for a period of 6 weeks with a standard diet or a diet containing the antioxidant  $\alpha$ -lipoic acid (1 g/kg).

Results—Superoxide anion production and NADPH oxidase activity were significantly enhanced in aorta and adipose tissue of Zucker Diabetic Fatty rats. Kinin B1 and B2 receptors expression levels were also significantly increased in the liver and the gastrocnemius muscle of Zucker Diabetic Fatty rats. Expression of both receptors was not altered in the pancreas of Zucker Diabetic Fatty rats and was undetectable in white retroperitoneal adipose tissue. Alpha-lipoic acid prevented the rise in NADPH oxidase activity in aorta and epididymal adipose tissue of Zucker Diabetic Fatty rats and the upregulation of kinin B1 receptor in liver and gastrocnemius muscle and that of kinin B2 receptor in the liver. Alpha-lipoic acid treatment was found to prevent the final body weight increase without affecting significantly hyperglycemia, hyperinsulinemia and insulin resistance index in Zucker Diabetic Fatty rats.

**Conclusion**—Findings support the hypothesis that oxidative stress is implicated in the induction of kinin B1 receptor in Zucker Diabetic Fatty rats. The ability of α-lipoic acid to blunt the body

# **Authors' Contributions**

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

<sup>\*</sup>Corresponding author: Réjean Couture, Department of Molecular and Integrative Physiology, Faculty of Medicine, Université de Montréal, PO Box 6128, Station City-Center, Montréal, Qc, H3C 3J7 Canada, Tel: 1 514 343 7060; Fax: 1 514 343 2111; rejean.couture@umontreal.ca.

Authors contributed equally to this work

weight gain appears to be mediated in part by preventing NADPH oxidase activity rise in adipose tissue and reversing the hepatic upregulation of kinin B1 receptor in Zucker Diabetic Fatty rats.

# Keywords

Alpha-lipoic acid; Diabetes; Kinin receptors; Obesity; Oxidative stress

# Introduction

Diabetes mellitus (DM) is defined by the World Health Organisation (WHO) as a metabolic disorder of multiple etiology. The global figure of people with diabetes is projected to increase to 333 million in 2025, and 430 million in 2030 [1]. This huge increase in diabetic population is due to aging, adoption of westernised lifestyle, physical inactivity and obesity [2]. Several hypotheses were suggested to explain the enhanced risks associated to diabetes; among these, one of the most plausible is an increase in oxidative stress. Oxidative stress may result from either excessive production of reactive oxygen species (ROS), especially the superoxide anion or from reduced antioxidant reserve. Previous studies have suggested that increased superoxide anion production may be involved in the pathogenesis and complications of diabetes and hypertension [3,4]. Studies have shown that  $\alpha$ -lipoic acid (LA), which is a powerful antioxidant, improved the insulin sensitivity in patients with type 2 diabetes [5]. Moreover, the treatment of insulin-resistant Zucker rats with  $\alpha$ -lipoic acid was found to increase both oxidative and non-oxidative glucose metabolism and to reduce insulin resistance [6]. In addition, LA was shown to prevent the development of insulin resistance and arterial hypertension as well as to decrease the body weight in chronically glucose-fed rats [7–10]. In obese patients with impaired glucose tolerance and dyslipidaemia, short-term treatment with LA (600 mg intravenously once daily over a period of 2 weeks) improved the insulin sensitivity and the plasma lipid profile [11]. The same treatment was found to decrease the levels of MDA, 8-iso-prostaglandin, TNF-α and IL-6 [11].

Kinins are important vasoactive peptides whose effects are mediated by two G-protein-coupled receptors (R), named kinin B2 receptor (constitutive) and kinin B1 receptor (inducible). They are involved in vascular homeostasis and cardiovascular diseases [12]. The kinin B2 receptor (B2R) is constitutively expressed troughout the body while the kinin B1 receptor (B1R) is virtually absent in healthy tissues, yet this receptor is induced by the cytokine pathway and the oxidative stress via the transcriptional nuclear factor kappa B (NF-κB) [12]. Studies from our laboratory have shown that treatments with LA or N-acetyl-L-cysteine, two potent antioxidants, prevented the upregulation of B1R in central and peripheral tissues in an hypertensive insulin-resistant rat model [8,13]. Moreover, α-lipoic acid therapy or 1-week treatment with SSR240612, a selective B1R antagonist, reduced hyperglycemia, hyperinsulinemia, insulin resistance, hypertension, body and epididymal fat gain, plasma lipids abnormalities and pain neuropathy in chronically glucose-fed rats [8,13–16]. On the other hand, investigations have shown that lack of both kinin B1 and B2 receptors enhanced nephropathy, neuropathy, and bone mineral loss in Akita type 1 diabetic mice [17]. Therefore discrepancies may exist between species and experimental models. The

expression and mode of regulation of kinin receptors in Zucker Diabetic Fatty (ZDF) rats, a classical model of type 2 diabetes, have not been investigated to date.

The present study was designed to evaluate the effect of supplemented LA diet (1 g/kg) on: 1- the expression of kinin B1 and B2 receptors at mRNA and protein levels in diabetes target organs (liver, pancreas, gastrocnemius skeletal muscle, white retroperitoneal adipose tissue); 2- superoxide anion production  $(O_2^{\bullet-})$  and NADPH oxidase activity (aorta and epididymal adipose tissue); and 3-plasma levels of glucose and insulin, insulin resistance (HOMA index) and body weight in ZDF rats.

# **Materials and Methods**

#### Animal care and treatments

This study was performed in Obese male ZDF (fa/fa) rats and lean male (ZL, fa/+) rats at 6 weeks of age (Charles River laboratories, St-Constant, Qc, Canada). Four groups of eight rats were divided randomly and treated for 6 weeks as follows: Group 1, ZDF rats were fed standard laboratory chow diet (SD); Group 2, ZDF rats were fed SD supplemented with alipoic acid (LA) (1g/kg feed); Group 3, ZL rats were fed SD; Group 4, ZL rats were fed SD supplemented with  $\alpha$ -lipoic acid (1g/kg feed). The LA supplemented diet was obtained from Ren's Feed Supplies Limited (Oakville, On, Canada). All rats were given tap water ad libitum. Body weight of each group of rats was measured at the beginning and at the end of the 6-week treatment with SD or LA. However, only data prior to sacrifice were presented to show the impact of LA on final body weight as the initial body weight prior to the 6-week treatment with SD or LA diet was not significantly different between Group 1 and Group 2 (ZDF) and between Group 3 and Group 4 (ZL). The rats were killed by decapitation after light anesthesia with CO<sub>2</sub>. After opening the thorax, blood was withdrawn into a vacutainer tube for plasma biochemistry. All blood samples were drawn early in the morning after fasting overnight (16 h). Organs and tissues (thoracic aorta, liver, pancreas, gastrocnemius skeletal muscle, retroperitoneal and epididymal adipose tissues) were rapidly harvested, frozen in liquid nitrogen and stored at -80°C until subsequent analysis. All research procedures and the care of the animals were in compliance with the guiding principles for animal experimentation as enunciated by the Canadian Council on Animal Care and were approved by the Animal Care Committee of our University.

# Plasma biochemistry

Plasma glucose concentrations were measured with a glucometer (Elite, Bayer Inc). Insulin levels were determined by radioimmunoassay (rat insulin RIA kit, Linco Research, St. Charles, USA) using 100  $\mu$ L of plasma. To estimate the degree of insulin resistance, we have used the Homeostasis Model Assessment (HOMA) index as calculated by the following formula: [insulin (in  $\mu$ U/mL)  $\times$  glucose (in mmol/L)]/22.5 [18].

#### Oxidative stress measurement

Production of superoxide anion  $(O_2^{\bullet-})$  was measured in thoracic aorta and epididymal fat tissue using the lucigenin-enhanced chemiluminescence method as described previously [19,20]. Briefly, for each animal, small slices from aorta and epididymal fat tissue were

preincubated in Krebs–HEPES buffer (saturated with 95%  $O_2$  and 5%  $CO_2$ , at room temperature for 30 min) and then transferred to glass scintillation vials containing 5  $\mu$ mol/L lucigenin for the determination of basal  $O_2^{\bullet-}$  levels. Lucigenin counts were expressed as counts per minute (cpm) per milligram of mass of tissue. Moreover, the activation of NADPH oxidase in the samples was assessed by adding 0.1 mmol/L NADPH to the vials before counting. Basal superoxide-induced luminescence was subtracted from the luminescence value induced by NADPH.

#### Western blot

Tissue protein quantification was performed with a bichinconic acid (BCA) kit (Thermo Scientific) using bovine serum albumin (BSA) as standard. Samples were run by electrophoresis on a 10% polyacrylamide gel and transferred onto nitrocellulose membranes. The efficiency of the overall procedure was monitored by Ponceau red staining. The membranes were blocked with a commercial blocking buffer (Thermo Scientific) in Phosphate Buffer Saline S-Tween 20, 0.1% (PBS-T). Membranes were then probed with our in house rabbit anti-B1R [21-23] or mouse anti-B2R (Cat no 610451, BD Transduction Laboratories, Lexington. USA) antibody diluted 1:1000. The secondary antibodies for B1R and B2R identification were an Horseradish Peroxidase (HRP)-linked goat anti-rabbit and an HRP-linked goat anti-mouse (Santa Cruz Biotech, CA, USA) used at a 1:25000 dilution, respectively. Antibodies incubation was performed in the commercial blocking buffer. Membranes were rinsed adequately between every step with PBS-T and revealed using an Enhanced Chemiluminescence Detection System (Super-Signal<sup>®</sup>, Thermo Scientific, Canada). Dynein was used as standard protein and revealed with mouse anti-dynein monoclonal antibody (Santa Cruz Biotech, CA, USA) diluted 1:25000. HRP-linked goat anti-mouse (Santa Cruz Biotech, CA, USA) was used as secondary antibody at a 1:25000 dilution. A quantitative analysis of the detected protein was performed by densitometry using an MCID<sup>™</sup> image analysis system (Imaging Research, St. Catharines, On, Canada).

### Total RNA extraction and SYBR green-based quantitative RT-PCR

The protocol for mRNA extraction, cDNA generation, SYBR green-based quantitative RT-PCR and quantification was described elsewhere [14,15]. Briefly, the PCR conditions were as follows: 95°C for 15 min, followed by 46 cycles at 94°C for 15 s, 60°C for 30s and 72°C for 30s. The Vector NTI-designed qPCR primers pairs are shown in Table 1. For standardization and quantification, rat 18S was amplified simultaneously. Relative gene expression values were expressed as fold change and were obtained by comparing ZDF to ZL rats.

# Statistical analysis

Data were expressed as the mean  $\pm$  SEM of values obtained from n rats. Statistical significance was determined with a one-way analysis of variance (ANOVA) followed by the post-hoc Bonferonni or Tukey-test for multiple comparisons and two-tailed unpaired student's t-test for single comparison. Only probability (P) values less than 0.05 were considered to be statistically significant.

# Results

# Effects of α-lipoic acid (LA) on body weight and metabolic parameters

As expected, the final body weight was significantly increased (P<0.01) in ZDF rats in comparison with ZL rats (Table 2). The supplementation of the diet with LA had no effect on this parameter in ZL rats, whereas it prevented the increase in final body weight in ZDF rats. As shown in Table 2, ZDF rats showed marked and significant increases (P<0.01) in plasma glucose and insulin levels as well as insulin resistance (HOMA index) in comparison with ZL rats. The treatment with LA did not affect significantly plasma glucose and insulin levels and insulin resistance in ZDF rats. Also, LA had no significant effect on these parameters in ZL rats.

# Effects of $\alpha$ -lipoic acid on oxidative stress parameters

As shown in Figure 1A and 2A, basal superoxide anion production was significantly (p <0.05) increased in aorta and epididymal fat tissues in ZDF rats in comparison with ZL rats. Six weeks of treatment with LA blocked significantly the rise in superoxide anion production in aorta and the difference between ZL and ZDF was no longer significant in the epididymal fat. As shown in Figures 1B and 2B, NADPH oxidase activity was significantly (p <0.05) increased in aorta and epididymal fat tissues of ZDF rats in comparison with ZL rats. Six weeks of treatment with LA abolished the rise in NADPH oxidase activity in both aorta and epididymal fat tissue in ZDF rats.

# Effect of $\alpha$ -lipoic acid on kinin receptors expression

B1R and B2R mRNA and protein expression levels were significantly increased in the liver (Figure 3) and the gastrocnemius muscle (Figure 4) of ZDF rats in comparison with ZL rats. A 6-week treatment with LA prevented the raised in B1R at mRNA and protein levels in the liver and gastrocnemius of ZDF rats while it had no effect on basal B1R expression in ZL rats (Figures 3 and 4). Protein and mRNA levels of B2R were reversed by LA in the liver but not in the gastrocnemius of ZDF rats (Figures 3 and 4). As shown in Figure 5, protein and mRNA expression levels of B1R and B2R in the pancreas were not significantly different in ZDF in comparison to ZL rats. Moreover, LA treatment had no effect on these parameters in those animals (Figure 5). Both B1R and B2R failed to be detected at mRNA and protein levels in the white adipose tissue of ZL and ZDF rats (Figure 6).

#### Discussion

The major findings of the present study are the following: 1- B1R and B2R expression at mRNA and protein levels were increased in the liver and the gastrocnemius muscle of ZDF rats, two key targets for fat and glucose metabolism; 2- NADPH oxidase activity and superoxide anion production were increased in aorta and adipose tissue of ZDF rats; 3-supplementation of LA in the diet prevented the rise in B1R at the mRNA and protein expression levels in liver and gastrocnemius muscle in ZDF rats; 4- LA reversed the increase in NADPH oxidase activity and superoxide anion in aorta and adipose tissue in ZDF rats; 5-the suppression of the NADPH oxidase activity and B1R expression with LA was accompanied by a dramatic reduction of body weight in ZDF rats, yet LA treatment failed to

affect hyperglycemia, hyperinsulinemia and insulin resistance in ZDF, a classical rat model of type 2 diabetes.

We have previously reported in a rat model of insulin resistance induced by chronic glucose feeding [8,13] and in hypertension induced by chronic infusion of angiotensin II [24] that the oxidative stress contributes to the induction and up-regulation of B1R in various tissues. The present study demonstrated that the treatment with LA prevented the increased expression of B1R along with the enhanced basal production of superoxide anion and NADPH oxidase activity in ZDF, supporting that the oxidative stress is also implicated in the induction and up-regulation of B1R in ZDF rats. This is in agreement with previous studies, which have demonstrated that the superoxide anion production is increased in the aorta and mesenteric arteries from ZDF rats [25,26].

While B1R and B2R were found to be absent in adipose tissue of ZDF rats as reported in insulin-resistant rats [16], B1R mRNA expression was increased and that of B2R decreased in adipose tissue of obese mice lacking leptin gene (ob/ob) [27]. These findings highlight species discrepancies regarding the presence of kinin receptors in adipose tissues. In addition, B1R mRNA levels were found to be increased in aorta and liver but not in skeletal muscle in ob/ob mice while B2R mRNA was not modified in those tissues [27]. Therefore, it appears that kinin receptors are regulated differently in ob/ob mice and ZDF rats even if both have defect in leptin function.

It is well known that the ZDF rat which represents a genetic model of metabolic syndrome suffers from obesity, type 2 diabetes, hypertension and dyslipidemia. Investigations have shown that treatment with resveratrol, a potent antioxidant reduced dyslipidemia and TNF-a in visceral adipose tissue of obese Zucker rats [28]. Importantly, we have shown in the present study that LA prevented the rise in the final body weight in ZDF rats. This is in agreement with a recent study which had demonstrated that LA induced prominent gene expression changes in liver in support of significant improvement of whole-body lipid status [29]. In addition, the present study showed that LA treatment prevented the increase in the NADPH oxidase activity in epididymal fat tissue as well as the rise in the liver B1R expression at mRNA and protein levels. This is in agreement with previous studies which have shown that lipoic acid attenuated the rise in vascular superoxide production in ZDF rats [26]. Thus, the present results suggest that oxidative stress through an overexpression of B1R is implicated in the elevation of body weight in ZDF rats. Our data support previous claims showing that B1R knockout mice or chronic blockade of B1R with SSR240612 decreases fat mass, increase energy expenditure and leptin sensitivity in mice treated with high-fat diet [30]. Similarly, 1-week treatment with the B1R antagonist SSR240612 reduced whole body and epididymal fat mass in high glucose feeding rats [16], supporting a role for B1R in obesity associated with type 2 diabetes.

In our study, B2R expression was also increased in the liver of ZDF rats by a mechanism sensitive to LA treatment. However, evidence suggests rather a protective role for B2R in insulin resistance and diabetes. The B2R is known to ameliorate insulin resistance by increasing glucose uptake and supply, and by inducing glucose transporter-4 translocation either directly or through phosphorylation of insulin receptor [31]. Resistance to insulin

occurs in B2R knockout mice, which is not compensated by the B1R [32]. B2R also provides cardio- and nephro-protection in ZDF rats [33,34]. Obese mice (ob/ob) lacking the B2R have similar body weight or fat accumulation, but showed increased fasting glycemia and impaired glucose tolerance when compared with ob/ob control mice, indicating insulin resistance and impaired glucose homeostasis [35].

In the present study, LA treatment was found to have no effect on hyperglycemia, hyperinsulinemia as well as the insulin resistance index even though it prevented completely the rise in superoxide anion production and NADPH oxidase activity in aorta and adipose tissue as well as the upregulation of B1R expression in liver and gastrocnemius muscle of ZDF rats. This is in agreement with a recent study [36], which has demonstrated that LA treatment did not decrease the rise in blood glucose levels and insulin resistance while it decreased the elevation of oxidative stress markers as reflected by the reduction in the protein carbonyls in skeletal muscle as well as in the urine conjugated dienes in obese female Zucker rats. Thus, the present study suggests that other mechanisms than B1R and oxidative stress are implicated in alteration of glucose metabolism in ZDF rats.

# **Conclusions**

The present study demonstrated that supplementation diet with LA prevented the upregulation of B1R in the liver and the gastrocnemius muscle indicating that oxidative stress is implicated in the induction of B1R in ZDF rats. In addition, treatment with LA prevented the increase in body weight but not hyperglycemia, hyperinsulinemia and insulin resistance in ZDF rats. The anti-obesity effect of LA seems to be associated with its anti-oxidative properties and suppression of B1R induction. Conversely, B1R and the oxidative stress do not appear to contribute to insulin resistance or glucose metabolic alteration in ZDF rats.

# **Acknowledgments**

This work was supported by a Grant-in-aids from the Canadian Institutes of Health Research (CIHR) (MOP-119329). ST holds a postdoctoral Fellowship from CIHR.

### References

- 1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27:1047–1053. [PubMed: 15111519]
- Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellituspresent and future perspectives. Nat Rev Endocrinol. 2011; 8:228–236. [PubMed: 22064493]
- 3. Jun T, Ke-yan F, Catalano M. Increased superoxide anion production in humans: a possible mechanism for the pathogenesis of hypertension. J Hum Hypertens. 1996; 10:305–309. [PubMed: 8817404]
- Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19:257–267. [PubMed: 8742574]
- 5. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, et al. Oral administration of RAC-alphalipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999; 27:309–314. [PubMed: 10468203]

 Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ, et al. The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes. 1996; 45:1024–1029. [PubMed: 8690147]

- El Midaoui A, Lungu C, Wang H, Wu L, Robillard C, Deblois D, Couture R. Impact of a-lipoic acid on liver peroxisome proliferator-activated receptor-a, vascular remodeling, and oxidative stress in insulin-resistant rats. Can J Physiol Pharmacol. 2011; 89:743–751. [PubMed: 21919742]
- 8. Lungu C, Dias JP, França CE, Ongali B, Regoli D, Moldovan F, Couture R. Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides. 2007; 41:375–387. [PubMed: 17988733]
- 9. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension. 2002; 39:303–307. [PubMed: 11847202]
- Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens. 2003; 16:173–179. [PubMed: 12620694]
- Zhang Y, Han P, Wu N, He B, Lu Y, et al. Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring). 2011; 19:1647–1653. [PubMed: 21593803]
- 12. Couture R, Blaes N, Girolami JP1. Kinin receptors in vascular biology and pathology. Curr Vasc Pharmacol. 2014; 12:223–248. [PubMed: 24568157]
- 13. Ismael MA, Talbot S, Carbonneau CL, Beauséjour CM, Couture R. Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance. Eur J Pharmacol. 2008; 589:66–72. [PubMed: 18555989]
- 14. Dias JP, Talbot S, Senecal J, Carayon P, Couture R. Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS One. 2010; 5:e12622. [PubMed: 20830306]
- 15. Dias JP, Couture R. Suppression of vascular inflammation by kinin B1 receptor antagonism in a rat model of insulin resistance. J Cardiovasc Pharmacol. 2012; 60:61–69. [PubMed: 22494994]
- 16. Dias JP, Couture R. Blockade of kinin B(1) receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance. Diabetes Obes Metab. 2012; 14:244–253. [PubMed: 22023455]
- 17. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, et al. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A. 2010; 107:10190–10195. [PubMed: 20479236]
- 18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412–419. [PubMed: 3899825]
- Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995; 95:187–194. [PubMed: 7814613]
- 20. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91:2546–2551. [PubMed: 8390482]
- 21. Lacoste B, Tong XK, Lahjouji K, Couture R, Hamel E. Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice. J Neuroinflammation. 2013; 10:57. [PubMed: 23642031]
- 22. Lin JC, Talbot S, Lahjouji K, Roy JP, Sénécal J, et al. Mechanism of cigarette smoke-induced kinin B(1) receptor expression in rat airways. Peptides. 2010; 31:1940–1945. [PubMed: 20637817]
- Pouliot M, Hétu S, Lahjouji K, Couture R, Vaucher E. Modulation of retinal blood flow by kinin B1, receptor in Streptozotocin-diabetic rats. Exp Eye Res. 2011; 92:482–489. [PubMed: 21420952]
- 24. Petcu M, Ongali B, El Midaoui A, de Champlain J, Couture R. Effects of alpha-lipoic acid on kinin B1 and B2 receptor binding sites in the spinal cord of chronically angiotensin-treated rats. Peptides. 2005; 26:1331–1338. [PubMed: 15878793]

 Vessières E, Guihot AL, Toutain B, Maquigneau M, Fassot C, et al. COX-2-derived prostanoids and oxidative stress additionally reduce endothelium-mediated relaxation in old type 2 diabetic rats. PLoS One. 2013; 8:e68217. [PubMed: 23874545]

- Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, et al. Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab. 2008; 10:64–74. [PubMed: 17970755]
- 27. Abe KC, Mori MA, Pesquero JB. Leptin deficiency leads to the regulation of kinin receptors expression in mice. Regul Pept. 2007; 138:56–58. [PubMed: 17184856]
- Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009; 77:1053–1063. [PubMed: 19100718]
- 29. Pashaj A, Yi X, Xia M, Canny S, Riethoven JJ, et al. Characterization of genome-wide transcriptional changes in liver and adipose tissues of ZDF (fa/fa) rats fed α-lipoic acid acid by next-generation sequencing. Physiol Genomics. 2013; 45:1136–1143. [PubMed: 24104204]
- 30. Mori MA, Araújo RC, Reis FC, Sgai DG, Fonseca RG, et al. Kinin B1 receptor deficiency leads to leptin hypersensitivity and resistance to obesity. Diabetes. 2008; 57:1491–1500. [PubMed: 18332096]
- 31. Couture R, Girolami JP. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol. 2004; 500:467–485. [PubMed: 15464053]
- 32. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, et al. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res. 2001; 88:275–281. [PubMed: 11179194]
- 33. Blaes N, Girolami JP. Targeting the 'Janus face' of the B2-bradykinin receptor. Expert Opin Ther Targets. 2013; 17:1145–1166. [PubMed: 23957374]
- 34. Schäfer S, Schmidts HL, Bleich M, Busch AE, Linz W. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol. 2004; 143:27–32. [PubMed: 15289289]
- 35. Barros CC, Haro A, Russo FJ, Schadock I, Almeida SS, et al. Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes. PLoS One. 2012; 7:e40573. [PubMed: 22829877]
- 36. Muellenbach EA, Diehl CJ, Teachey MK, Lindborg KA, Archuleta TL. Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat. Metabolism. 2008; 57:1465–1472. [PubMed: 18803954]




Figure 1. Effect of 6-week treatment with  $\alpha$ -lipoic acid or standard diet (SD) on superoxide anion production (A) and NADPH oxidase activity (B) in aorta of 12 weeks Zucker diabetic fatty (ZDF) rats and age matched Zucker lean (ZL) rats. \*P<0.05 vs ZL rats; \*P<0.05 and \*#P<0.01 vs ZDF rats.




Figure 2. Effect of 6-week treatment with  $\alpha$ -lipoic acid or standard diet (SD) on superoxide anion production (A) and NADPH oxidase activity (B) in epididymal fat tissue of 12 weeks Zucker diabetic fatty (ZDF) rats and age-matched Zucker lean (ZL) rats. \*P<0.05 vs ZL rats; #P<0.05 vs ZDF rats.




Figure 3. Effect of 6-week treatment with  $\alpha$ -lipoic acid (LA) or standard diet (SD) on the expression of kinin B1R (A, C, E) and B2R (B, D, F) in the liver of 12 weeks Zucker diabetic fatty (ZDF) rats and age-matched Zucker lean (ZL) rats. Shown are mRNA (A, B) and protein (C–F) expression levels of B1R (37 kDa) and B2R (42 kDa). Dynein (75 kDa) and 18S mRNA were used as standards. Data are the mean  $\pm$  S.E.M of 3–8 rats/group. Statistical comparison with ZL (\*) and ZD (+) in SD is indicated by \*,+ P<0.05; \*\* P<0.01; \*\*\*,+++ P<0.001.




Figure 4. Effect of 6-week treatment with α-lipoic acid (LA) or standard diet (SD) on the expression of kinin B1R (A, C, E) and B2R (B, D, F) in the gastrocnemius skeletal muscle of 12 weeks Zucker diabetic fatty (ZDF) rats and age-matched Zucker lean (ZL) rats. Shown are mRNA (A, B) and protein (C–F) expression levels of B1R (37 kDa) and B2R (42 kDa). Dynein (75 kDa) and 18S mRNA were used as standards. Data are the mean  $\pm$  S.E.M of 3–8 rats/group. Statistical comparison with ZL (\*) and ZD (+) in SD is indicated by ++ P<0.01; \*\*\*,+++ P<0.001.




Figure 5. Effect of 6-week treatment with  $\alpha$ -lipoic acid (LA) or standard diet (SD) on the expression of kinin B1R (A, C, E) and B2R (B, D, F) in the pancreas of 12 weeks Zucker diabetic fatty (ZDF) rats and age-matched Zucker lean (ZL) rats. Shown are mRNA (A, B) and protein (C–F) expression levels of B1R (37 kDa) and B2R (42 kDa). Dynein (75 kDa) and 18S mRNA were used as standards. Data are the mean  $\pm$  S.E.M of 3–8 rats/group.




Figure 6. Expression levels of kinin B1R (A, C) and B2R (B, D) in the white adipose tissue of 12 weeks Zucker diabetic fatty (ZDF) rats and age-matched Zucker lean (ZL) rats. Shown are mRNA (A, B) and protein (C, D) expression levels of B1R (37 kDa) and B2R (42 kDa). Dynein (75 kDa) and 18S mRNA were used as standards. Data are the mean  $\pm$  S.E.M of 3–8 rats/group.

Midaoui et al.

Table 1

qPCR primer pairs sequences.

|                     |    | Sequences   |    | P(  | Position |     | Gen Bank Accession number |
|---------------------|----|---|----|-----|----------|-----|---------------------------|
| 18S Forward         | 2, | 5' TCA ACT TTC GAT GGT AGT CGC CGT 3' 363 -                       | 3′ | 363 | I        | 386 | 201117                    |
| 18S Reverse         | 2, | TCC TTG GAT GTG GTA GCC GTT TCT 3' 470 -                          | 3′ | 470 | I        | 447 | A01117                    |
| B1 receptor Forward | 2, | B1 receptor Forward 5' GCA GCG CTT AAC CAT AGC GGA AAT 3' 367 -   | 3′ | 367 | I        | 391 | NIM 020051                |
| B1 receptor Reverse | 2, | B1 receptor Reverse 5′ CCA GTT GAA ACG GTT CCC GAT GTT 3′ 478   - | 3′ | 478 | Ι        | 454 | 100000_MM                 |
| B2 receptor Forward | 2, | B2 receptor Forward 5′ AGG TGC TGA GGA ACA ACG AGA TGA 3′ 882 -   | 3′ | 882 |          | 905 | NW 172100                 |
| B2 receptor Reverse | 2, | B2 receptor Reverse 5' TCC AGG AAG GTG CTG ATC TGG AAA 3' 990 -   | 3′ | 066 |          | 296 | 001C/T_MM                 |

Page 16

# Table 2

Effect of 6-week treatment with α-lipoic acid (LA) on basal metabolic parameters in 12 weeks old Obese Zucker diabetic fatty (ZDF) rats and agematched Zucker lean (ZL) rats.

Midaoui et al.

|                         |       | ZF |       | IZ                   | ZL + LA | A     |        | ZDF |                    | Z      | ZDF + LA | LA      |
|-------------------------|-------|----|-------|----------------------|---------|-------|--------|-----|--------------------|--------|----------|---------|
| Final body weight (g)   | 312   | +1 | 9     | 305                  | +1      | 9     | 365    | +1  | ** 6               | 326    | +1       | ++ 5    |
| Plasma glucose (mmol/L) | 5.8   | +1 | ± 0.4 | 5.3                  | +1      | 0.3   | 16.8   | +1  | 1.8 **             | 12.9   | +1       | 1.7     |
| Plasma insulin (pmol/L) | 471.5 | +1 | 36.5  | 471.5 ± 36.5 520.6 ± | +1      | 130.2 | 2098.9 | +1  | ± 313.5** 2087.0 ± | 2087.0 | +1       | 253.9   |
| HOMA index              | 18.0  | +1 | 1.9   | 17.5                 | +1      | 4.3   | 271.9  | +1  | 30.9** 182.4       | 182.4  | +1       | ** 6.03 |

Data are means  $\pm$  SEM obtained from 8 rats in each group.

\*\* P < 0.01 vs ZL rats,  $^{++}$ P < 0.01 vs ZDF rats.

Intra-assay coefficient of variance for glucose and insulin in each group are: ZL (19.51, 21.90), ZL + LA (16.01, 70.74), ZDF (30.30, 42.52) and ZDF + LA (37.27, 34.29), respectively.

Page 17